RESEARCH ARTICLE

Placental peptides metabolism and maternal factors as predictors of risk of gestational diabetes in pregnant women. A case-control study

Robert Amadu Ngala¹*, Linda Ahenkorah Fondjo¹, Peter Gmagna¹, Frank Naku Ghartey², Martin Akilla Awe³

¹ Department of Molecular Medicine, School of Medical Science, Kwame Nkrumah University of Science and Technology (KNUST), Kumasi, Ghana. ² Department of Chemical Pathology, University of Cape Coast, Cape Coast- Ghana

* rngala2000@yahoo.com

Abstract

Background
Gestational diabetes is a risk factor for perinatal complications; include shoulder dystocia, birth injuries such as bone fractures and nerve palsies. It is associated with later development of type 2 diabetes, the risk of macrosomia and other long-term health effects of infants born to diabetic mothers. The study assesses placental peptides and maternal factors as potential predictors of gestational diabetes among pregnant women.

Material and methods
A total of 200 pregnant women were recruited for the study, 150 pregnant women without pregestational diabetes including 50 women with low risk factors of diabetes as controls and 50 other pregnant women with pregestational diabetes as control. Fasting blood glucose and the lipid profile were determined by enzymatic methods using Envoy® 500 reagents (Vital Diagnostics, USA). Glycated haemoglobin was assessed using the Cation Exchange resin method. Leptin and the Human Placenta Lactogen were assayed using the Sandwich-ELISA technique. Beta chorionic gonadotrophin, insulin, progesterone and estradiol were determined using chemilumiscence immunoassay technique on MAGLUMI 600 analyzer. Anthropometry, including BMI and blood pressure were also measured.

Results
Fasting plasma glucose (FBG), insulin, insulin resistance, glycated haemoglobin and Human Placenta Lactogen(HPL)were significantly (p<0.0001) increased in the pregestational diabetic women whereas progesterone and estradiol were significantly decreased. In the second trimester however, there was no significant difference (p>0.05) in estradiol, insulin, insulin resistance and HPL between the pregnant women who developed gestational diabetes and those who did not. Leptin, progesterone and FBG were significantly increased
in those who developed GDM. The risk of developing gestational diabetes increased with overweight (OR = 1.76, P = 0.370) and family history of diabetes (OR = 2.18, P = 0.282).

Conclusion

Leptin, progesterone, estradiol estimated in this study were increased in the gestational diabetes mellitus women and fairly predicted gestational diabetes in the non-diabetics pregnant women. Obesity, aging and family history of diabetes were strongly predictive of gestational diabetes.

Introduction

In a normal pregnancy, sensitivity to insulin reduces with increasing gestation age [1]. It is a physiological programming designed to shift metabolic fuel to the fetus for development [2]. In this state, insulin sensitivity in pregnant non-diabetics is reportedly reduced [3]. The decrease in insulin sensitivity with progression in pregnancy is due partly to the inhibitory effect of placenta peptides (C-reactive protein, leptin and human placental lactogen etc) on insulin secretion [4,5]. The effects of these placenta peptides and hormones cause the enlargement of the islets of Langerhans cells and or the hyperplasia of the pancreatic β-cells [6] to increase the secretion of more insulin, resulting in compensated hyperinsulinaemia [7]. Obesity and chronic insulin resistance during pregnancy are most common factors that exacerbate β-cell dysfunction [8]. Gestational diabetes mellitus (GDM) occurs when the pancreatic β-cells are unable to produce sufficient insulin to offset the persisting insulin resistance in pregnant women [3].

Similar frequencies of HLA-DR2, DR3 and DR4 antigens in GDM as in healthy pregnant women have been reported and this has been found to be associated with low prevalence of autoimmune destruction of β-cells and therefore rules out the possibility that GDM is a disease of autoimmune origin [9].

Gestational diabetes mellitus is reported in 2 to 9 percent of all pregnancies, [10] it is a risk factor for adverse perinatal complications that may later result in the development of type 2 diabetes [11]. The long-term health effects on infants born to mothers with gestational diabetes include impaired glucose tolerance [12], obesity [13] and impaired intellectual ability [14].

Pregnant women with high risk factors for GDM or showing clinical signs of diabetes are usually subjected to an oral glucose tolerance test (OGTT) at first trimester and then again between 24 and 28 weeks if the initial tests were negative. At weeks 24–28 of gestation, it is recommended that all women undergo an OGTT. GDM is defined as a fasting plasma glucose level ≥ 5.5 mmol/l and/or a 2-h plasma glucose level ≥ 8.5 mmol/l after a fasting 75-g OGTT [15]. Treatment of gestational diabetes reduces perinatal morbidity and may also improve the woman’s health-related quality of life [16].

Screening for GDM is limited, the standard screening procedure for diabetes and prediabetes, such as fasting blood glucose and glycated haemoglobin, are not recommended for screening for GDM. At first trimester FBG alone does not distinguish between GDM, impaired glucose tolerance or preexisting diabetes, also HbA1c predicts glucose metabolic state over a period of 3 months and therefore does not distinguish between preexisting diabetes and GDM. However, the recommended method is an oral glucose tolerance test (OGTT) [17] and this is expensive, invasive, and requires hospital visit and multiple blood draws.
The development of abnormal glucose metabolism after gestational diabetes can be predicted readily by means of available clinical and anthropometric measurements.\cite{18, 19} Similarly, if there were a proper assessment of the various risks as well as markers that may predict the onset of gestational diabetes among pregnant women, it would in turn allow practitioners to better manage patients and prevent many pregnancy associated complications. The current study therefore was aimed at assessing the roles of placental peptides and maternal factors as potential predictors of gestational diabetes among pregnant women in the Tema Metropolis of Ghana.

**Methods**

A cross-sectional case-control study was carried out at the Tema General Hospital, Tema Polyclinic and Provita Specialist Hospital all in Ghana, from March 2014 to March 2015. A total of 200 pregnant women aged between 17–45 years and mean age of 28.43±4.95 years were recruited for the study, comprising of 150 pregnant women without pregestational diabetes (subjects) including 50 women in the group with low risk factors of diabetes as controls. Fifty (50) other pregnant women with pregestational diabetes were recruited as controls.

**Study participant selection**

To determine gestational diabetes in pregnant women, a standard OGTT was performed between the 24\textsuperscript{th} and 28\textsuperscript{th} week of gestation after an overnight fast (8–12 hours), by administering 75 g anhydrous glucose in 300 ml water. Women were advised to follow a normal diet 48 hours before the oral glucose-tolerance test (OGTT). However, pregnant women belonging to high risk diabetes population were screened during the first trimester in order to detect a previously undiagnosed diabetes mellitus. Gestational age was also determined on the basis of the woman’s last normal menstrual period and if it coincided within 1 week of the date determined by ultrasound done between 16\textsuperscript{th} and 20\textsuperscript{th} weeks of gestation, otherwise the ultrasound estimates was used. A pretested guided questionnaire was administered to collect demographic data of family history of diabetes, parity, miscarriages, and complications of pregnancy. Anthropometric parameters including BMI and blood pressures were measured. Pregnant women who reported at the antenatal clinic were included; unless they opted out of the study, non pregnant women seeking fertility advice were excluded from the study.

**Ethical clearance approval**

Ethical clearance was obtained from the Committee on Human Research and Publications Ethics (CHRPE)(REF) of the School of Medical Sciences (SMS), Kwame Nkrumah University of Science & Technology (KNUST).

**Informed consent of subjects**

Clients who reported at the antenatal clinic and agreed to participate in the study gave written informed consent after detailed explanation of the study procedures had been given to them before the recruitment into the study. Guardians of participants below 18 years of age gave consent on their behalf.

**Sample collection**

An over-night (8–12hr) fasted sample of 6ml venous blood sample was taken from subjects during the first trimester and between the 24\textsuperscript{th} and 28\textsuperscript{th} week of gestation. The sample was dispensed into gel separator tubes (yellow top), EDTA (mauve top) and Fluoride tubes (for
glucose) for analysis. Blood samples were allowed to clot. After clotting, samples were centrifuged at 3000 g for 4 min and the sera separated into appropriate tubes and frozen at -20˚C until analysis. Metabolites analyzed for included total cholesterol, triglyceride (TG), low-density lipoprotein (LDL), high-density lipoprotein (HDL), fasting blood glucose serum insulin, glycosylated haemoglobin, leptin, estradiol, progestrone, Human placenta lactogen and beta HCG. The homeostasis model assessment index-insulin resistance (HOMA-IR), based on fasting insulin and glucose measured in a single blood sample, was used to calculate insulin resistance [20].

Biochemical analysis
The frozen serum samples were thawed to room temperature before being analyzed.

Lipid profile
Triglycerides, total cholesterol and HDL-cholesterol were assayed using enzymatic methods with Envoy 500 reagents (Vital Diagnostics, USA) according to the manufacture’s specification on BT 5000 Random Access Chemistry Analyzer (Biotecnica, Italy).

Glycated haemoglobin
The Cation Exchange Resin method for the selective estimation of glycated haemoglobin (HbA1c) method in human whole blood was used, on Microtech 3000 semi auto analyzer.

Leptin
Maternal serum leptin concentration was measured quantitatively by Sandwich-ELISA technique using Leptin (Human LEP) kit (Elabscience Biotechnology co ltd WuHan P.R.C). The lowest limit of detection of the assay was 0.094ng/mL. The intra assay and inter assay CV ranged from 2.5% to 9.5% and from 4.7% to 8.3%, respectively.

Human placenta lactogen (HPL)
Maternal serum Human placenta lactogen concentration was measured quantitatively by Sandwich-ELISA technique on Human Reader HS, a semi auto analyzer.

Progestrone (P4) and estradiol (E2)
Progestrone and Estradiol, were determined using chemilumiscence immunoassay technique on MAGLUMI 600 analyzer. The method uses ABEI label anti- E2/anti-prog antibody and a purified E2/ Prog antigen to coat magnetic microbeads. The ABEI labeled microbeads were incubated at 37˚C forming antigen antibody complex which was precipitated in a magnetic field and the supernatant descanted. The addition of starter I and 2 initiates chemilumiscence reaction, and the light signal produced measured.

Beta chorionic gonadotrophin (β-HCG) and Insulin assay
Beta chorionic gonadotrophin and insulin were also determined using MAGLUMI 600 analyzer. The sandwich chemilumiscence immunoassay technique was used, adhering to the manufacturers’ protocol.
Statistical analysis

Results were expressed as mean ± S.D and statistical analysis performed using SPSS version 20.0 (SPSS Inc.) and GraphPad prism 5 for Windows. Normal distribution and homogeneity of the variances were tested using Kolmogorov-Smirnov and Levene tests, respectively. Student t-test was used to compare the significance of the difference in the mean values of any two groups and chi square analysis was used to compare frequency between the two groups. Linear regression analysis was used to study the correlation between the parameters. Correlations between parameters were analyzed using the Pearson R test for variables with normal distribution and ROC to determine the sensitivity and specificity of FBG, HbA1c, Insulin and β-HCG as markers of GDM. P<0.05 was considered statistically significant.

Results

Table 1 show 50 women with pre-gestational diabetes (controls) and 150 pregnant women without diabetes (cases) during first trimester, 50 of which have very low risk of developing diabetes. Fasting plasma glucose, insulin, insulin resistance, glycedated haemoglobin, and Human Placenta Lactogen were significantly increased (p<0.0001) in the pregestational

| Variable                | Cases (n = 150) | Controls (n = 50) | P-value |
|-------------------------|----------------|------------------|---------|
| Age (Mean± SD)          | 29.08±5.26     | 27.78±4.67       | 0.136   |
| FBG (mmol/l)            | 4.28 ± 0.91    | 5.86 ± 2.03      | <0.001  |
| HB (mg/dl)              | 10.28 ± 1.83   | 10.32 ± 1.72     | 0.886   |
| HbA1c (%)               | 4.70 ± 1.53    | 5.56 ± 1.12      | <0.0001 |
| Blood Pressure (mmHg)   |                |                  |         |
| SBP                     | 114.91 ± 6.07  | 115.34 ± 6.59    | 0.669   |
| DBP                     | 82.66 ± 7.82   | 82.88 ± 7.78     | 0.861   |
| BMI n (Kg/m²)           | 23.29 ± 3.40   | 24.75 ± 3.51     | 0.010   |
| BMI n (%)               |                |                  | 0.161   |
| Underweight             | 2 (1.3)        | 0 (0.0)          |         |
| Normal                  | 97 (64.7)      | 28 (56.0)        |         |
| Overweight              | 48 (32.0)      | 18 (36.0)        |         |
| Obese                   | 3 (2.0)        | 4 (8.0)          |         |
| TC (mmol/L)             | 4.97 ± 1.36    | 5.25 ± 1.02      | 0.194   |
| TG (mmol/L)             | 1.32 ± 0.79    | 1.45 ± 0.89      | 0.354   |
| β-HCG                   | 4880.07 ± 554.13 | 4923.04 ± 390.67 | 0.612   |
| Insulin (μIU/mL)        | 14.43 ± 7.76   | 18.51 ± 9.30     | 0.003   |
| IR (μIU/mL)             | 2.75 ± 1.76    | 4.81 ± 2.90      | <0.0001 |
| Leptin (ng mL⁻¹)        | 24.12 ± 9.6    | 22.89 ± 9.4      | 0.232   |
| P4 (ng/ml)              | 60.50 ± 21.91  | 44.86 ± 14.82    | <0.0001 |
| E2 (pg/ml)              | 4249.94 ± 1592.88 | 2470.52 ± 1297.95 | <0.0001 |
| HPL (μg/ ml)            | 75.70 ± 23.46  | 105.11 ± 21.35   | <0.0001 |

p < 0.05 was considered statistically significant

FBG; fasting blood glucose, HB; haemoglobin, HbA1c; glycated haemoglobin, SBP; systolic blood pressure, DBP; diastolic blood pressure, BMI; body mass index, TC; total cholesterol, TG; triglyceride, β-HCG; beta-human chorionic gonadotropin, IR; insulin resistant, P4; Progesterone, E2; Estradiol, HPL; Human Placenta Lactogen

https://doi.org/10.1371/journal.pone.0181613.t001
diabetic controls, whereas, progesterone and estradiol were significantly increased in the non-diabetic pregnant women. BMI was also significant ($p < 0.05$) increased in pregnant women with pregestational diabetes (Table 1).

After screening for gestational diabetes among the pregnant women without diabetes ($n = 150$), between 24–28 week gestation, 12 of them developed GDM giving a prevalence of 8% GDM. Fasting plasma glucose, glycated haemoglobin, leptin, and progesterone were significantly ($p < 0.0001, p = 0.029, p < 0.0001, p = 0.043$ respectively) increased in the pregnant women who developed GDM. Estradiol and HPL were non significantly changed in the GDM women, whilst plasma haemoglobin was higher in the women without GDM (Table 2).

When the pregnant women were stratified according to age, pregnant women less than 20yrs of age did not present with GDM, whilst, 33.3% of them in the age range of 20–29yrs had GDM. The highest prevalence of 58.3% GDM occurred at 30–39yrs, whilst only 8.3% GDM was found in the 40–49yrs range (Fig 1).

Pregnant women who developed GDM had significantly ($p < 0.01$) raised fasting blood glucose, ($p < 0.014$), BMI ($P = 0.022$), leptin, progesterone, estradiol ($p < 0.0001$) than the pregnant women with low risk of diabetes (Table 3) but significantly low ($p < 0.0001$) human placenta lactogen levels.

Table 2. Comparison of biochemical variables in case subjects who developed GDM and those without GDM in the second trimester.

| Variable          | GDM          | No GDM       | P-value       |
|-------------------|--------------|--------------|---------------|
|                   | (n = 12)     | (n = 138)    |               |
| FBG (mmol/l)      | 6.33 ± 1.03  | 4.27 ± 0.90  | <0.0001       |
| HB (mg/dl)        | 9.23 ± 2.83  | 10.37 ± 1.70 | 0.035         |
| HbA1c (%)         | 5.62 ± 2.92  | 4.62 ± 1.33  | 0.029         |
| Glycemic control  |              |              | 0.007         |
| ≤ 7% (Good)       | 10 (83.3)    | 135 (97.8)   |               |
| > 7% (Poor)       | 2 (16.7)     | 3 (2.2)      |               |
| Blood Pressure (mmHg) |            |              |               |
| SBP               | 115.00 ± 4.99| 114.90 ± 6.17| 0.955         |
| DBP               | 82.42 ± 7.45 | 82.68 ± 7.88 | 0.913         |
| BMI n (Kg/m^2)    | 21.8 ± 2.85  | 23.41 ± 3.42 | 0.116         |
| BMI n (%)         |              |              | 0.118         |
| Underweight       | 1 (8.3)      | 1 (0.7)      |               |
| Normal            | 6 (50.0)     | 91 (65.9)    |               |
| Overweight        | 5 (41.7)     | 43 (31.2)    |               |
| Obese             | 0 (0.0)      | 3 (2.2)      |               |
| TC (mmol/L)       | 5.09 ± 0.81  | 4.96 ± 1.40  | 0.751         |
| TG (mmol/L)       | 1.53 ± 0.11  | 1.31 ± 0.77  | 0.363         |
| β-HCG             | 5000.0 ± 0.00| 4869.65 ± 576.70 | 0.436     |
| Insulin (0μIU/mL) | 17.17 ± 11.38| 14.30 ± 7.37 | 0.221         |
| IR (μIU/mL)       | 3.50 ± 2.75  | 2.68 ± 1.64  | 0.120         |
| leptin (ng mL^{-1}) | 36.5 ± 9.2  | 19.8 ± 9.0  | <0.0001       |
| P4 (ng/ml)        | 72.76 ± 11.54| 59.43 ± 22.30| 0.043         |
| E2 (pmol/L)       | 4502.01 ± 1338.39| 4228.02 ± 1615.44 | 0.569     |
| HPL (μg/ ml)      | 66.45 ± 27.43| 76.50 ± 23.02| 0.155         |

p < 0.05 was considered statistically significant
FBG: fasting blood glucose, HB: haemoglobin, HbA1c: glycated haemoglobin, SBP: systolic blood pressure, DBP: diastolic blood pressure, BMI: body mass index, TC: total cholesterol, TG: triglyceride, β-HCG: beta-human chorionic gonadotropin, P4: Progesterone, E2: Estradiol, HPL: Human Placenta Lactogen

https://doi.org/10.1371/journal.pone.0181613.t002
Table 3. Biochemical comparison between pregnant women who developed GDM (cases) and pregnant women with low risk of diabetes (controls).

| Variable               | GDM           | Controls      | P-value |
|------------------------|---------------|---------------|---------|
|                        | (n = 12)      | (n = 50)      |         |
| FBG (mmol/l)           | 5.86 ± 2.03   | 4.33 ± 1.03   | 0.014   |
| HB (mg/dl)             | 9.22 ± 2.83   | 10.32 ± 1.72  | 0.086   |
| HbA1c (%)              | 5.62 ± 2.92   | 5.56 ± 1.11   | 0.900   |
| Glycemic control       |               |               | 0.223   |
| ≤ 7%                   | 10 (83.3)     | 47 (94.0)     |         |
| > 7%                   | 2 (16.7)      | 3 (6.0)       |         |
| Blood Pressure (mmHg)  |               |               |         |
| SBP                    | 115.00 ± 4.99 | 115.34 ± 6.59 | 0.868   |
| DBP                    | 82.42 ± 7.45  | 82.88 ± 7.78  | 0.853   |
| BMI n (Kg/m²)          | 21.80 ± 2.85  | 20.12 ± 2.40  | 0.022   |
| BMI n (%)              |               |               | 0.153   |
| Underweight            | 1 (8.3)       | 5 (10.0)      |         |
| Normal                 | 4 (33.3)      | 30 (60.0)     |         |
| Overweight             | 5 (41.7)      | 15 (30.0)     |         |
| Obese                  | 2 (16.6)      | 0 (0.0)       |         |
| TC (mmol/L)            | 5.09 ± 0.812  | 5.25 ± 1.23   | 0.630   |
| TG (mmol/L)            | 1.53 ± 1.11   | 1.45 ± 0.89   | 0.799   |
| β-HCG                  | 5000.00 ± 0.00| 4923 ± 390.67 | 0.500   |
| Insulin (µIU/mL)       | 17.17 ± 11.38 | 18.51 ± 9.30  | 0.668   |
| IR (µIU/mL)            | 3.50 ± 2.75   | 4.81 ± 2.90   | 0.163   |
| leptin (ng mL⁻¹)       | 37.5 ± 7.2    | 18.8 ± 6.0    | <0.0001 |
| P4 (ng/ml)             | 72.76 ± 11.54 | 44.86 ± 14.82 | <0.0001 |
| E2 (pmol/L)            | 4502.01 ± 1338.39 | 2470.52 ± 1297.95 | <0.0001 |
| HPL (µg/ ml)           | 66.45 ± 27.43 | 105.11 ± 21.35| <0.0001 |

Comparison between means was done using un-paired t-test. p < 0.05 was considered statistically significant

FBG: fasting blood glucose, HB: haemoglobin, HbA1c: glycated haemoglobin, SBP: systolic blood pressure, DBP: diastolic blood pressure, BMI: body mass index, TC: total cholesterol, TG: triglyceride, β-IR: insulin resistant, β-HCG: beta-human chorionic gonadotropin, P4: Progesterone, E2: Estradiol, HPL: Human Placenta Lactogen

https://doi.org/10.1371/journal.pone.0181613.t003
Table 4 shows the Accuracy of diagnosis of first trimester FBG-1, FBG-2, HbA1c, Insulin, β-HCG, P4, E2 and HPL.

| Threshold values | Sensitivity (95% CI) | Specificity (95% CI) | AUC (95% CI) | P-value |
|------------------|----------------------|----------------------|--------------|---------|
| GDM              |                      |                      |              |         |
| FBG 1 (mmol/L) 3.75 | 33.3% (9.93–65.1)    | 72.0% (64.2–79.7)    | 0.49 (0.31–0.67) | 0.928   |
| FBG 2 (mmol/L) 5.6 | 100% (73.5–100)      | 95.7% (90.8–98.4)    | 0.99 (0.97–1.00) | <0.0001 |
| HbA1c (%) 5.6     | 33.3% (9.93–65.1)    | 87.0% (80.2–92.1)    | 0.53 (0.33–0.72) | 0.8004  |
| Insulin (μIU/mL) | 41.7% (15.2–72.3)    | 94.1% (88.7–97.4)    | 0.51 (0.28–70)  | 0.9244  |
| B-HCG 4947        | 100% (73.5–100)      | 7.65 (3.0–12.0)      | 0.53 (0.37–0.70) | 0.7084  |
| P4 74.95          | 58.3% (27.7–84.8)    | 71.0% (62.7–78.4)    | 0.67 (0.54–0.79) | 0.050   |
| E2 5256           | 50.0% (21.1–78.9)    | 63.0% (54.4–71.1)    | 0.53 (0.38–0.68) | 0.737   |
| HPL 65.61         | 50% (21.1–78.9)      | 71.7 (63.5–79.1)     | 0.59 (0.39–0.79) | 0.305   |

FBG; fasting blood glucose, HB; haemoglobin, HbA1c; glycated haemoglobin, SBP; systolic blood pressure, DBP; diastolic blood pressure, BMI; body mass index, TC; total cholesterol, TG; triglyceride, β-HCG; beta-human chorionic gonadotropin, IR: insulin resistant, P4; Progesterone, E2; Estradiol, HPL; Human Placenta Lactogen

Table 4 shows the Accuracy of diagnosis of first trimester FBG-1, FBG-2, HbA1c, Insulin, β-HCG, P4, E2 and HPL.

The diagnostic value of 3.75 mmol/L for first trimester fasting blood glucose (FBG-1) had a sensitivity of 33.3% and Specificity of 72.0% as marker for GDM and 5.6 mmol/L diagnostic value with significant (p < 0.0001) 100% sensitivity and 95.7% specificity for second trimester fasting blood glucose (FBG-2). First trimester HbA1c with sensitivity of 33.3% and specificity of 87.0% had a threshold value of 5.6%.

β-HCG showed 100% sensitivity and specificity at 4947. E2 and HPL showed similar sensitivity of 50.0% but difference in specificity of 63.0% and 71.7% at 5256 and 65.61 respectively.

The risk of developing GDM increased with age (OR = 1.02, P = 0.757). Overweight (OR = 1.76, P = 0.370) and family history of diabetes (OR = 2.18, P = 0.282) (Table 5). Pregnant women in the first trimester, with a history of abortion, miscarriage and pre-mature birth as complications had higher risk of developing GDM. Also the risk of developing GDM increased with increasing plasma progesterone.

Body mass index was significantly and positive correlated with Glycated haemoglobin (.702*). Insulin resistance was positively associated with insulin concentration (.922**) and FBG (.714**) in the women with GDM. Glycated haemoglobin was positively associated with fasting blood glucose (-.510**) but negatively associated with β-HCG (-303**) (Table 6) and fasting blood glucose levels negatively associated with β-HCG (-.469**) and progesterone (-.298*)

Discussion

Pregnancy has been identified as a diabetogenic condition characterized by the development of insulin resistance and hyperinsulinemia [7]. It has been proposed that pregnancy-induced insulin resistance reveals the onset of β-cell defects associated with insulin resistance and hyperglycaemia, hyperlipidaemia [21], which underlie GDM. GDM is diabetes restricted to pregnant women in whom the development of glucose intolerance was first diagnosed during pregnancy, distinguishing it from preexisting glucose intolerance and diabetes induced by pregnancy [21, 22]. This study was aimed at assessing placental peptides and maternal factors as potential predictors of the development of gestational diabetes among pregnant women.

The pre-gestational diabetic pregnant women had significantly higher plasma glucose, insulin and insulin resistance than the non diabetic pregnant women (Table 1). The plasma glucose
and insulin resistance in the non diabetic pregnant women were significantly low probably due to the early stage of pregnancy. However, it has been shown that insulin resistance is associated with normal pregnancy and may not develop into GDM [23]. The mechanisms leading to insulin resistance in normal pregnancy are explained by several theories including; the estrogen and progesterone hormone counter effect on insulin action by their inhibitory effect on the skeletal muscle \( \beta \)-subunit of the insulin receptor and insulin receptor substrate-1 [23] and thereby making available enough glucose for the growing foetus [24]. These changes in insulin signaling reduces insulin-mediated glucose uptake in the muscle, the major tissues for whole-body glucose disposal [25]. However, insulin resistance is terminated soon after delivery and normal glucose metabolism returns within 1 year postpartum [26].

Table 5. Logistic regression for predictors of gestational diabetes mellitus.

| Predictors                          | OR (95% CI)    | P-value |
|-------------------------------------|----------------|---------|
| Age (years)                         | 1.02 (0.91–1.13) | 0.757   |
| SBP (mmHg)                          | 1.00 (0.91–1.10)  | 0.963   |
| DBP (mmHg)                          | 0.99 (0.92–1.07)  | 0.897   |
| BMI n (%)                           |                |         |
| Underweight                         | 15.17 (0.84–27.35) | 0.065   |
| Normal*                             | Reference      |         |
| Overweight                          | 1.76 (0.51–6.10)  | 0.370   |
| Obese                               |                |         |
| Family History of other conditions |                |         |
| None*                               | Reference      |         |
| Diabetes                            | 2.18 (0.53–9.06)  | 0.282   |
| Obesity                             |                |         |
| Hypertension                        |                |         |
| Thyroid disease                     | 0.77 (0.09–6.01)  | 0.814   |
| History of Full term delivery       |                |         |
| Yes                                 | 0.59 (0.18–1.97)  | 0.393   |
| No*                                 | Reference      |         |
| History of Abortions                |                |         |
| Yes                                 | 1.86 (0.45–7.43)  | 0.382   |
| No*                                 | Reference      |         |
| History of Miscarriages             |                |         |
| Yes                                 | 1.30 (0.15–11.25) | 0.810   |
| No*                                 | Reference      |         |
| History of Pregnancy Complications  |                |         |
| None                               | Reference      |         |
| Pre-eclampsia                       |                |         |
| Pre-mature birth                    | 1.27 (0.15–10.99) | 0.826   |
| Still birth                         |                |         |
| \( \beta \)-HCG                     | 1.12 (0.00–4.85)  | 0.994   |
| Insulin (\( \mu \)IU/mL)           | 1.04 (0.97–1.12)  | 0.256   |
| P4 (ng/ml)                          | 1.04 (1.00–1.09)  | 0.050   |
| E2 (pmol/L)                         | 1.00 (1.00–1.00)  | 0.707   |
| HPL (\( \mu \)g/ ml)               | 0.98 (0.95–1.01)  | 0.105   |

SBP; systolic blood pressure, DBP; diastolic blood pressure, BMI; body mass index, \( \beta \)-HCG; beta-human chorionic gonadotropin P4; Progesterone, E2; Estradiol, HPL; Human Placenta Lactogen

https://doi.org/10.1371/journal.pone.0181613.t005
This phenomenon of insulin resistance in normal pregnancy was observed in this study. There was no significant difference, in plasma insulin, insulin resistance, β-HCG (P = 0.436) and the lipid profile between pregnant women diagnosed with GDM and pregnant women with no diabetes at the early weeks of gestation (Table 2). This seems to suggest that, these peptides and the lipids may not play significant roles in the aetiology of GDM.

However, as the gestation progresses the effect of placenta peptides; Progesterone, estradiol, leptin and glycated haemoglobin insulin predisposes the women to glucose intolerance and eventually to overt GDM [27, 28, 29]. Progesterone, and estradiol were significantly (p < 0.0001) increased in the cases compared to the controls (Table 1). Progesterone, estradiol and leptin were also significantly higher in women with GDM than women with low risk of developing GDM (Table 3). This phenomenon may account for the role of these placenta peptides in the aetiology of GDM. Women with GDM have a combination of acquired and chronic insulin resistance and are more insulin resistant compared to the normal women during late pregnancy. The phosphorylation of insulin receptor tyrosine is implicated in the transmission of insulin signal to enable glucose uptake [30]. In women with GDM, there is a significant decrease

### Table 6. Relationship between glycated haemoglobin, placenta peptides and dyslipidemia among pregnant women with GDM (upper portion) and those without diabetes (lower portion).

| Variables | HbA1c | FBG | β-HCG | Insulin | IR | BMI | P4 | HPL | E2 | TC | TG |
|-----------|-------|-----|-------|---------|----|-----|----|------|----|----|----|
| HbA1c     | r     | 1   | 0.25  | -0.096  | -0.087 | .702* | 0.073 | -0.167 | 0.352 | -0.104 | 0.555 |
| P-value   | 0.434 | .   | 0.766 | 0.788   | 0.011 | 0.821 | 0.604 | 0.261  | 0.748 | 0.061 |
| FBG       | 0.510** | 1   | .a   | 0.427  | .714** | 0.163 | -0.409 | -0.518 | -0.13  | -0.369 | 0.244 |
| P-value   | 0     | .   | 0.166 | 0.009   | 0.613 | 0.187 | 0.084 | 0.686  | 0.237 | 0.445 |
| β-HCG     | r     | -0.303* | .469** | .a   | .a   | .a   | .a   | .a   | .a   | .a   | .a   |
| P-value   | 0.033 | 0.001 | .   | .   | .   | .   | .   | .   | .   | .   |
| Insulin   | r     | -0.125 | -0.014 | 0.071 | 1   | .922** | -0.097 | -0.293 | -0.314 | -0.448 | -0.144 | -0.238 |
| P-value   | 0.388 | 0.921 | 0.622 | 0.763 | 0.356 | 0.32  | 0.144 | 0.655  | 0.457 |
| IR        | r     | 0.193 | 0.545** | -0.172 | -0.803** | 1   | -0.084 | -0.357 | -0.403 | -0.455 | -0.223 | -0.159 |
| P-value   | 0.178 | 0.231 | 0   | 0.796 | 0.254 | 0.194 | 0.138 | 0.486  | 0.623 |
| BMI       | r     | -0.008 | -0.105 | -0.237 | -0.17 | -0.176 | 1   | 0.142  | -0.161 | 0.576  | 0.024  | 0.438 |
| P-value   | 0.958 | 0.47  | 0.097 | 0.239 | 0.221 | .659 | 0.618 | 0.05   | 0.942  | 0.154 |
| P4        | r     | -0.144 | -.298* | 0.162 | 0.237 | 0.02  | -0.092 | 1     | 0.524  | 0.235  | 0.003  | -0.212 |
| P-value   | 0.318 | 0.035 | 0.261 | 0.098 | 0.891 | 0.525 | 0.08  | 0.461  | 0.994  | 0.509 |
| E2        | r     | 0.142 | 0.066 | 0.133 | -0.206 | -0.155 | 0.155 | 0.014  | 0.282  | 1     | 0.076  | 0.372 |
| P-value   | 0.325 | 0.651 | 0.357 | 0.152 | 0.284 | 0.282 | 0.924 | 0.374  | 0.814  | 0.234 |
| HPL       | r     | 0.114 | -0.063 | 0.077 | -0.114 | -0.117 | 0.058 | 0.149  | 1     | -0.219 | -0.247 | -0.551 |
| P-value   | 0.431 | 0.666 | 0.593 | 0.431 | 0.42  | 0.69  | 0.3   | 0.126  | 0.439  | 0.064 |
| TC        | r     | 0.18  | 0.12  | -0.144 | 0.129 | 0.144 | 0.172 | 0.027  | 0.126  | 0.138  | 1     | 0.413 |
| P-value   | 0.211 | 0.407 | 0.318 | 0.372 | 0.318 | 0.232 | 0.851 | 0.384  | 0.341  | 0.182 |
| TG        | r     | 0.186 | 0.011 | -0.027 | -0.011 | -0.004 | 0.052 | -0.203 | 0.041  | .314*  | 0.187  | 1     |
| P-value   | 0.196 | 0.938 | 0.852 | 0.941 | 0.98  | 0.717 | 0.158 | 0.777  | 0.026  | 0.193  |

R = Correlation coefficient
*Correlation is significant at the 0.05 level (2-tailed)
**Correlation is significant at the 0.01 level (2-tailed)
aNot be computed because at least one of the variables is constant.

FBFBG; fasting blood glucose, HB; haemoglobin, HbA1c; glycated haemoglobin, SBP; systolic blood pressure, DBP; diastolic blood pressure, BMI; body mass index, TC; total cholesterol, TG; triglyceride, β-HCG; beta-human chorionic gonadotropin; P4; Progesterone, E2; Estradiol, HPL; Human Placenta Lactogen

https://doi.org/10.1371/journal.pone.0181613.t006
in insulin receptor tyrosine phosphorylation in the skeletal muscle, and a decrease in insulin-stimulated glucose uptake [30]. Therefore, pregnancy can unmask slight defects that induce GDM. It has been proposed that these peptides interfere with insulin phosphorylation during pregnancy and impair glucose uptake [29].

The mean plasma leptin in the non diabetics pregnant women was nonsignificantly raised (Table 1), probably due to the smaller number of the women (12/150) who developed GDM had high leptin levels. This assertion is verified in Table 3, where leptin levels in GDM women is significantly higher than in women with low risk of GDM. Leptin concentration in amniotic fluid at 15–17 weeks of gestation is higher in women who subsequently developed GDM than in women with normal glucose tolerance during pregnancy [31]. Leptin enhances peripheral insulin sensitivity and improves pancreatic β-cell function [32]. These normal functions of leptin are disrupted in leptin resistance state of pregnancy inducing insulin resistance and impaired glucose tolerance in pregnancy [33,34]. The placenta produces leptin during pregnancy resulting in further hyperleptinaemia. This is exacerbated by hyperleptinaemia due to fat accumulation, and subsequent insulin resistance, giving rise to GDM in women who are unable to compensate for the physiological dysregulation.

Anthropometric changes have been implicated in the aetiology of GDM. BMI was significantly (p = 0.022) higher in GDM women compared to pregnant women with low risk of GDM (Table 3). The risk of developing gestational diabetes increased with overweight (OR = 1.76, P = 0.370) (Table 5). Similar findings reported by Chu et al., shows that the risk of developing GDM is about 2 and 4 times higher among overweight and obese women respectively, as compared to normal-weight pregnant women [35].

Aging is a major confounding factor associated with the development of GDM. Even though the odd ratio of developing GDM due to ageing was low (OR = 1.02, P = 0.757) (Table 5), women within the age range of 30–39 had the highest probability of developing GDM (58%), whilst those at 20yrs and below had the lowest probability of 0.0%. (Fig 1). As women advance in age, there is a tendency to increased BMI, adiposity, multiparity and high blood pressure, and these are all confounding factors of GDM[36].

Apart from age, and BMI, other confounding factors that predisposes pregnant women to the development of GDM, include, family history of diabetes, ethnicity, adiposity and parity [37]. In a North American population, higher rates of GDM were reported among blacks, Hispanics, and Asians compared to non-Hispanic whites [38, 39]. A family history of diabetes increased the odds of developing GDM (OR = 2.18, P = 0.282). Pregnant women with a history of abortion, miscarriage and pre-mature birth as complications had higher risk of developing GDM (Table 5). The risk of developing GDM increased with increasing plasma insulin (OR 1.04 P = 0.256) and progesterone (OR 1.04 P = 0.05). Also the placental peptides were significantly higher in women who developed GDM than those who had low risk for the development of GDM (Table 3). Progesterone also had a strong sensitivity and specificity in diagnosing GDM, whilst β-HCG, estradiol and HPL were poor predictors of GDM.

Glycated haemoglobin, fasting blood glucose and fasting plasma insulin, are the key markers of diabetes. None of the placenta peptides and hormones had a significant specificity and selectivity as a marker of GDM in the first trimester. However, plasma glucose of diagnostic value of 5.6mmol/l had significant specificity and selectivity as marker of GDM in the second trimester (Table 4).

Body mass index was significantly and positively correlated with glycated haemoglobin (.702*). Fasting blood glucose had an inverse and strong significant correlation (-.801**) with insulin levels among GDMs (Table 6). Though, HbA1c, insulin and β-HCG are useful metabolites for diagnoses and monitoring of diabetes mellitus, yet had fair diagnostic tests values for GDM, since the AUC (95% CI) were >0.05. Glycosylated haemoglobin is not usually used
clinically to diagnose GDM, it is however useful in diagnosing pre-existing diabetes in early pregnancy [40].

The area under the ROC for FBG-1 (at first trimester) was 0.49 suggesting that fasting plasma glucose level in the first trimester is a poor diagnostic test for gestational diabetes mellitus. However, AUC for FBG-2 was 0.99 implying that FBG-2 is a good diagnostic test for diagnosing GDM between 24wks-28 wks, whereas, glycated haemoglobininsulin and β-HCG were poor diagnostic test markers for GDM as compared to FBS-2 (Fig 2).

**Conclusion**

The crude prevalence of GDM in the metropolis was 8.0%. The plasma level of the placenta peptides, Leptin, Progesterone and Estradiol estimated were increased in the women who developed gestational diabetes mellitus. These peptides were fair in predicting GDM. However, progesterone level in the first trimester was outstanding in predicting the onset of GDM. Underweight, overweight, age and history of diabetes were strong predictors of GDM. HbA1c, insulin and β-HCG are fair tests for predicting GDM.

**Limitations**

The effect of some confounding factors, ethnicity, adiposity on gestational diabetes were not independently determined.
Acknowledgments
The authors are grateful to the Medical Directors and staff of Tema General Hospital, Bethel Hospital Provita Hospital and Tema Polyclinic.

Author Contributions
Conceptualization: Robert Amadu Ngala.
Data curation: Peter Gmagna.
Formal analysis: Peter Gmagna, Martin Akilla Awe.
Investigation: Peter Gmagna, Martin Akilla Awe.
Methodology: Peter Gmagna, Martin Akilla Awe.
Project administration: Linda Ahenkorah Fondjo.
Software: Frank Naku Ghartey, Martin Akilla Awe.
Supervision: Robert Amadu Ngala, Linda Ahenkorah Fondjo.
Validation: Peter Gmagna, Frank Naku Ghartey.
Visualization: Robert Amadu Ngala, Linda Ahenkorah Fondjo.
Writing – original draft: Robert Amadu Ngala.
Writing – review & editing: Linda Ahenkorah Fondjo, Frank Naku Ghartey.

References
1. Barbour LA, McCurdy CE, Hernandez TL, Kirwan JP, Catalano PM, and Friedman JE. Cellular mechanisms for insulin resistance in normal pregnancy and gestational diabetes. Diabetes care 2007; 30: 2S112–119
2. King JC. Maternal obesity, metabolism, and pregnancy outcomes. Annu. Rev. Nutr. 2006; 26:271–291. https://doi.org/10.1146/annurev.nutr.24.012003.132249 PMID: 16704347
3. Buchanan T.A. and Xiang A.H. Gestational diabetes mellitus. The Journal of clinical investigation. 2005: 115: 485–491. https://doi.org/10.1172/JCI24531 PMID: 15765129
4. Wolf M, Sandler L, Hsu K, Vossen-Smirnakis K, Ecker JL, Thadani R. First-Trimester C-Reactive Protein and Subsequent Gestational Diabetes Diabetes Care. 2003; 26:819–824, PMID: 12610043
5. Qiu C, Williams MA, Vadachkoria S, Frederick IO, Luthy DA. Increased maternal plasma leptin in early pregnancy and risk of gestational diabetes mellitus. Obstetrics & Gynecology 2004; 103:519–25. https://doi.org/10.1093/73128 PMID: 10700229
6. Ramiya VK, Maraist M, Arfors KE, Schatz DA, Peck AB and Cornelius JG. Reversal of insulin-dependent diabetes using islets generated in vitro from pancreatic stem cells. Nature medicine 2000; 6: 278–282 https://doi.org/10.1038/73128 PMID: 10700229
7. Ryan EA, O’Sullivan MJ, Skyler JS: Insulin action during pregnancy: studies with the euglycemic clamp technique. Diabetes. 1985: 34:380–389, PMID: 3882502
8. Buchanan TA, Xiang A, Kjos SL and Watanabe R. What is gestational diabetes? Diabetes Care 2007; 30: S105–S111 https://doi.org/10.2337/dc07-s201 PMID: 17596457
9. Kuhl C. Etiology and pathogenesis of Gestational Diabetes Diabetes Care. 1998; 21: B19–B21 PMID: 9704223
10. Hoffman L, Nolan C, Wilson JD, Oats J, Simmons D. Gestational diabetes mellitus—management guidelines: the Australasian Diabetes in Pregnancy Society. Med J Aust 1998; 169:93–97 PMID: 9700346
11. O’Sullivan J. The Boston Gestational Diabetes Studies. In: Sutherland HW, Stowers JM, Pearson DWM, eds. Carbohydrate metabolism in pregnancy and the newborn. London: Springer-Verlag, 1989:287–94.
12. Silverman B, Metzger BE, Cho NH, Loeb CA. Impaired glucose tolerance in adolescent offspring of diabetic mothers: relationship to fetal hyperinsulinism. Diabetes Care. 1995; 18:611–617 PMID: 8585997
13. Petitt D, Bennett PH, Knowler WC, Baird HR, Aleck KA. Gestational diabetes mellitus and impaired glucose tolerance during pregnancy: long-term effects on obesity and glucose intolerance in the offspring. Diabetes Care 1985; 34:119–122

14. Rizzo TA, Metzger BE, Dooley SL, Cho NH. Early malnutrition and child neurobehavioural development: insights from the study of children of diabetic mothers. Child Dev. 1997; 68:26–38 PMID: 9084122

15. American Diabetes Association. Standards of Medical Care in Diabetes—2013. Diabetes Care. 2013; 36 (Suppl 1):S11–S66.

16. Crowther CA, Hiller JE, Moss JR McPhee AJ, William JS, and Robinson JS. Effect of Treatment of Gestational Diabetes Mellitus on Pregnancy Outcomes N Engl J Med. 2005; 352:2477–248 https://doi.org/10.1056/NEJMoa042973 PMID: 15951574

17. Basevi V, Di Mario S, Morciano C, Nonino F, Magrini N. Comment on: American Diabetes Association. Standards of medical care in diabetes-2011. Diabetes Care. 2011; 34:S11–S61

18. Mamabolo RL, Alberts M, Levitt NS, Delemarre-van de Waal HA, and Steyn NP. Prevalence of gestational diabetes mellitus and the effect of weight on measures of insulin secretion and insulin resistance in third-trimester pregnant rural women residing in the Central Region of Limpopo Province, South Africa. Diabetic medicine: a journal of the British Diabetic Association. 2007; 24: 233–239.

19. Lee AJ, Fanazca RJH, Franzcog PW, Franzcog SPW, Franzcog MP. Gestational Diabetes Mellitus: Clinical Predictors and Long-Term Risk of Developing Type 2 Diabetes A retrospective cohort study using survival analysis Diabetes Care. 2007; 30:878–883, https://doi.org/10.2337/dc06-1816 PMID: 17392549

20. Matthews DR, Hosker JP, Rudenski AS, Nalor BA, Treacher DF and Turner RC. Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man Diabetologia 1985; 28: 412–419 PMID: 3899825

21. Sattar N, Greer I. Pregnancy complications and maternal cardiovascular risk: opportunities for intervention and screening? Br Med J. 325:157–160, 2002

22. American Diabetes Association: Gestational diabetes mellitus. Diabetes Care. 2000; 23: S77–S79.

23. Metzger BE, Buchanan TA, Coustan DR, De Leiva A, Dunger DB, Hadden DR et al. Summary and Recommendations of the Fifth International Workshop-Conference on Gestational Diabetes Mellitus Diabetes Care. 2007; 30, S251–S260 https://doi.org/10.2337/dc07-s225 PMID: 17596481

24. Lain KY and Catalano PM. Metabolic changes in pregnancy. Clinical obstetrics and gynecology. 2007; 50: 938–948 https://doi.org/10.1097/GRF.0b013e31815a5494 PMID: 17982337

25. Kelley DE, He J, Menshikova EV, and Ritov VB. Dysfunction of Mitochondria in Human Skeletal Muscle in Type 2 Diabetes. Diabetes. 2005; 54: 2944–2950, PMID: 12351431

26. Coustan RD, Carpenter MW O’Sullivan PS, Carr RS. Gestational diabetes: Predictors of subsequent disordered glucose metabolism American Journal of Obstetrics and Gynecology. 1993; 168: 1139–114 PMID: 8475959

27. Desoye G, and Hauguel-de Mouzon S, The Human Placenta in Gestational Diabetes Mellitus The insulin and cytokine network Diabetes Care. 2007; 30:S120–S126 https://doi.org/10.2337/dc07-e203 PMID: 17596459

28. Handwerger S, Freemark M: The roles of placental growth hormone and placental lactogen in the regulation of human fetal growth and development.J Pediatr Endocrinol Metab 2000; 13:343–356, PMID: 10776988

29. Brelje TC, Scharp DW, Lacy PE, Ogren L, Talamanes F, Robertson M, Friessen HG, Sorenson RL: Effect of homologous placental lactogens, prolactins, and growth hormones on islet B-cell division and insulin secretion in rat, mouse, and human islets: implication for placental lactogen regulation of islet function during pregnancy. Endocrinology. 1993; 132:879–887, https://doi.org/10.1210/endo.132.2.8425500 PMID: 8425500

30. Friedman JE, Ishizuka T, Shao JL, Huston L Highman T and Catalano P Impaired glucose transport and insulin receptor tyrosine phosphorylation in skeletal muscle from obese women with gestational diabetes. Diabetes.1999; 48:1807–1814 PMID: 10480612

31. D’Anna R, Baviera G, Corrado F, Robertton M, Friessen HG, Sorenson RL: Plasma homocysteine in early and late pregnancies complicated with preeclampsia and isolated intrauterine growth restriction. Acta obstetricia et gynecologica Scandinavica 2004; 83:155–8. PMID: 14756732

32. Rabe K., Lehrke M., Parhofer K.G. and Broedl U.C. Adipokines and insulin resistance. Molecular medicine.2008; 14: 741–751

33. Hauguel-de Mouzon S and Guerre-Milio M. The placenta cytokine network and inflammatory signals. Placenta. 2006; 27: 794–798. https://doi.org/10.1016/j.placenta.2005.08.009 PMID: 16242770
34. Hauguel-de Mouzon S, Lepercq J Catalano P. The known and unknown of leptin in pregnancy. American Journal of Obstetrics and Gynecology. 2006; 194: 1537–1545. https://doi.org/10.1016/j.ajog.2005.06.064 PMID: 16731069

35. Chu S.Y., Callaghan W.M., Kim S.Y., Schmid C.H., Lau J., England L.J. and Dietz P.M. Maternal obesity and risk of gestational diabetes mellitus. Diabetes Care. 2007; 30: 2070–2076. https://doi.org/10.2337/dc06-2559a PMID: 17416786

36. Freinkel N, Metzger BE, Phelps RL, Dooley SL, Ogata ES, Radvany RM. Gestational Diabetes Mellitus: Heterogeneity of Maternal Age, Weight, Insulin Secretion, HLA Antigens, and Islet Cell Antibodies and the Impact of Maternal Metabolism on Pancreatic B-Cell and Somatic Development in the Offspring. Diabetes, 1985; 34; 2: 1–7

37. Rodrigues S, Robinson EJ, Ghezzo H and Gray-Donald K Interaction of body weight and ethnicity on risk of gestational diabetes mellitus. Am J Clin Nutr 1999; 70:1083–9. PMID: 10584054

38. Green JR, Pawson IG, Schumacher LB, Perry J, Kretchmer N. Glucose tolerance in pregnancy: ethnic variation and influence of body habitus. Am J Obstet Gynecol 1990; 163:86–92. PMID: 2375375

39. Berkowitz GS, Lapinski RH, Wein R, Lee D. Race/ethnicity and other risk factors for gestational diabetes. Am J Epidemiol 1992; 135:965–73. PMID: 1595695

40. Sacks DB, Arnold M, Bakris GL, Bruns DE, Horvath AR, Kirkman MS, et al. Guidelines and recommendations for laboratory analysis in the diagnosis and management of diabetes mellitus. Diabetes Care. 2011; 34: e61–e99. https://doi.org/10.2337/dc11-9998 PMID: 21617108